- Home
- GTM vs ZLAB Comparison
GTM vs ZLAB Comparison
Compare GTM & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GTM
- ZLAB
- Stock Information
- Founded
- GTM 2007
- ZLAB 2013
- Country
- GTM United States
- ZLAB China
- Employees
- GTM N/A
- ZLAB N/A
- Industry
- GTM
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- GTM
- ZLAB Health Care
- Exchange
- GTM NYSE
- ZLAB Nasdaq
- Market Cap
- GTM 3.4B
- ZLAB 3.6B
- IPO Year
- GTM N/A
- ZLAB 2017
- Fundamental
- Price
- GTM $11.22
- ZLAB $37.17
- Analyst Decision
- GTM Buy
- ZLAB Buy
- Analyst Count
- GTM 2
- ZLAB 5
- Target Price
- GTM $12.00
- ZLAB $54.28
- AVG Volume (30 Days)
- GTM 3.4M
- ZLAB 746.2K
- Earning Date
- GTM 08-04-2025
- ZLAB 08-07-2025
- Dividend Yield
- GTM N/A
- ZLAB N/A
- EPS Growth
- GTM N/A
- ZLAB N/A
- EPS
- GTM 0.12
- ZLAB N/A
- Revenue
- GTM $1,209,900,000.00
- ZLAB $418,326,000.00
- Revenue This Year
- GTM N/A
- ZLAB $44.07
- Revenue Next Year
- GTM $2.39
- ZLAB $49.13
- P/E Ratio
- GTM $97.00
- ZLAB N/A
- Revenue Growth
- GTM N/A
- ZLAB 43.72
- 52 Week Low
- GTM $7.01
- ZLAB $16.01
- 52 Week High
- GTM $13.39
- ZLAB $44.34
- Technical
- Relative Strength Index (RSI)
- GTM N/A
- ZLAB 55.44
- Support Level
- GTM N/A
- ZLAB $33.55
- Resistance Level
- GTM N/A
- ZLAB $37.98
- Average True Range (ATR)
- GTM 0.00
- ZLAB 1.12
- MACD
- GTM 0.00
- ZLAB 0.26
- Stochastic Oscillator
- GTM 0.00
- ZLAB 75.25
About GTM ZOOMINFO TECHNOLOGIES INC
ZoomInfo Technologies Inc provides a go-to-market intelligence platform for sales and marketing teams. Its cloud-based go-to-market data and insights platform deliver comprehensive and high-quality intelligence and analytics to provide sales and marketing professionals with accurate information and insights on the organizations and professionals. Nearly all of its revenue is derived from the United States.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.